Ale

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ale

What is Ale? A Foundational Overview

Property Description
Active Ingredient Atorvastatin
Form Oral Film-Coated Tablet
Pharmacological Class Statin (HMG-CoA Reductase Inhibitor)
General Purpose Lipid-lowering agent (for high cholesterol)
Origin Synthetic Compound

Defining Ale and Its Core Classification

Ale is a synthetic, prescription-only medicine containing the active substance Atorvastatin. Its pharmacological class is defined as a statin, which is technically an HMG-CoA reductase inhibitor. This classification identifies it as a highly specific agent engineered to influence the body's lipid (fat) metabolism. Ale is commercially positioned as a reliable, single-ingredient product, typically offered by its manufacturer in a distinctive film-coated tablet format for oral administration. This presentation is clinically recognized for its controlled disintegration, which aids in reliable absorption of the Atorvastatin compound. Atorvastatin is categorized as an essential medication for its role in treating high lipid levels.


How Does Ale Generally Help the Body?

Ale functions as a highly effective lipid-lowering agent whose general purpose is to manage abnormally high fat levels, such as hypercholesterolemia, in the blood. Its primary therapeutic goal is to achieve substantial reduction in harmful Low-Density Lipoprotein Cholesterol (LDL-C) and total cholesterol levels. The drug accomplishes this by applying its physiological action to the liver, where it acts as a selective inhibitor of the enzyme that catalyzes the rate-limiting step in the body's own cholesterol synthesis process. This mechanism serves to reduce internally produced cholesterol. This targeted intervention is intended for patients needing to rebalance their lipid profile; for instance, as part of a regimen for managing mixed dyslipidemia. The medication’s use for this purpose is based on its inhibition of key metabolic pathways.

Regulatory References

  1. WHO Essential Medicines List

What side effects are possible with Ale?

Official Adverse Reactions and Safety Profile

The safety profile of Ale (Atorvastatin) is formally classified by government regulatory authorities into frequency tiers and System Organ Classes (SOCs) to detail documented adverse reactions. These classifications provide an evidence-based description of potential risks.

Regulatory Frequency Framework

Classification Examples of Reactions (SOC Grouping)
Common (up to 1 in 10 people) Nasopharyngitis, Headache, Myalgia, Constipation, Abnormal liver function tests (Musculoskeletal, Gastrointestinal, Nervous System)
Uncommon (up to 1 in 100 people) Insomnia, Dizziness, Vomiting, Alopecia, Fatigue (Psychiatric, Nervous System, Skin)
Rare (up to 1 in 1,000 people) Myopathy, Pancreatitis, Cholestasis, Tendinopathy (Musculoskeletal, Gastrointestinal, Hepatobiliary)

Serious Safety Considerations

The official labeling highlights several serious adverse reactions, which, though rare, are clinically significant. These include rhabdomyolysis (a severe form of muscle breakdown) and hepatic failure, which have been documented in post-marketing reports. The risk of serious muscle effects can be increased when Atorvastatin is co-administered with certain interacting medicines, as defined in regulatory safety documentation.

Population-Specific Safety Notes

The medicine is contraindicated in individuals with active liver disease or unexplained persistent elevations in serum transaminases, which constitutes a critical safety restriction. For older adults and pediatric patients, the safety profile documented in clinical studies is considered similar to that observed in the general adult population.

Overdose and Emergency Response

The official regulatory documentation for Ale (Atorvastatin) strictly defines the required response to a suspected overdose, emphasizing procedural management rather than documenting a specific list of acute symptoms. Within the regulatory framework, no specific manifestations of acute overdose have been formally established or reported in clinical trials, which directs the entire emergency response toward supportive care.

Immediate medical attention is required upon suspected overdose. Regulators mandate that management must be symptomatic and supportive, conducted under professional medical supervision. This care includes clinical monitoring and ensuring the maintenance of vital signs until the patient achieves stability.

A critical constraint noted in the official prescribing information is the absence of a specific counteracting agent: no specific antidote is known or available to reverse the effects of an overdose. Furthermore, the regulatory profile is constrained by the drug's high plasma protein binding; consequently, advanced procedures such as hemodialysis are not expected to significantly enhance clearance of the drug. The absence of specific overdose notes for populations like pediatrics or those with impaired liver function means standard supportive care principles apply across patient groups. This approach characterizes the overdose structure as being reliant on essential, non-specific life support measures.

Therapeutic Uses of Ale

What Ale treats: main uses and benefits

Ale is generally used in conditions characterized by systemic imbalance, primarily focused on managing the systemic imbalance of blood lipids and providing supportive management against major symptomatic risks.

The medication is commonly used across conditions presenting with periods of heightened symptoms related to elevated fat levels in the bloodstream, including primary hypercholesterolemia, mixed dyslipidemia, and the familial forms of high cholesterol. Ale is considered relevant for easing the risk of future, acute symptomatic episodes, such as myocardial infarction (heart attack) and stroke, offering therapeutic support in high-risk scenarios, including for patients with Type 2 Diabetes. This use is generally relevant for chronic management.

“This therapeutic strategy may assist the patient during episodes of heightened discomfort linked to chronic vascular disease.”

Ale is applied across domains where additional symptomatic support is needed, assisting specialized patient groups, such as adolescents with inherited, severe forms of high cholesterol. This supportive management contributes to easing the overall symptom load related to high lipids and assists with maintaining functional stability during periods of heightened systemic burden.

Quick Fact: Relief for Lipid Imbalance
Ale plays a role in managing the symptoms related to systemic imbalance by assisting with the management of elevated LDL-C and Triglycerides.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Who Can and Cannot Use Ale?

Ale (Atorvastatin) is subject to strict population eligibility rules defined by official government regulatory documents.


Populations for Whom Use is Contraindicated

Category Official Regulatory Status
Active Hepatic Disease Contraindicated in patients with active liver disease or unexplained, persistent elevations of serum transaminases.
Reproductive Status Contraindicated in pregnant women (or those who may become pregnant) and breastfeeding mothers.
Hypersensitivity Contraindicated for individuals with a known allergy to atorvastatin or any component of the product.

Age and Conditional Use Restrictions

Ale is generally approved for adult patients. For pediatric patients, use is restricted to individuals aged 10 years and older and only for specific conditions like Familial Hypercholesterolemia. Use is not established in children younger than 10 years for general indications.

Regulatory documentation requires special consideration for patients with certain predisposing factors for myopathy, which include advanced age (65 years and older), uncontrolled hypothyroidism, and renal impairment. Women of child-bearing potential are required to use appropriate contraception during treatment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official interaction profile for Ale (Atorvastatin) is based on the drug's metabolism and transport, defining specific constraints and prohibitions for co-administration with other substances.

Classification Interacting Agents (Official Regulatory Basis)
Formally Contraindicated Cyclosporine, Glecaprevir/Pibrentasvir, and Gemfibrozil are prohibited combinations as defined in official prescribing information.
Exposure-Altering Agents Strong CYP3A4 inhibitors (e.g., Clarithromycin, Itraconazole, certain HIV/HCV protease inhibitors) and transporter inhibitors (OATP1B1, BCRP inhibitors) significantly increase Ale's plasma concentrations.
Risk-Enhancing Agents Co-administration with Colchicine or other Fibric Acid Derivatives (e.g., Fenofibrate) increases the officially documented risk of muscle-related events.

Official regulatory documents require that co-administration with Rifampin be simultaneous to prevent a reduction in Ale's plasma concentration. Conversely, Ale can officially increase the plasma levels of co-administered medicines, including Oral Contraceptives and Digoxin. Regarding non-medicinal products, consumption of large quantities of Grapefruit juice is not recommended due to its potential to increase Ale's systemic exposure. Furthermore, Ale concentrations are officially markedly increased in patients with chronic alcoholic liver disease.

Mechanism of Action

Ale's mechanism of action is based on a targeted, two-step process occurring primarily in the liver, coordinated with downstream effects on vascular pathways.

Targeted Enzyme Blockade and Reduced Internal Production

This domain covers the molecular interaction where Ale selectively and competitively inhibits HMG-CoA Reductase, the primary enzyme in the liver responsible for the body’s own cholesterol synthesis via the mevalonate pathway. This inhibition reduces the concentration of cholesterol inside the liver cells, which triggers a compensatory mechanism that ultimately leads to systemic changes.

Enhanced Systemic Lipoprotein Clearance

The drop in internal cholesterol concentration signals the liver cells to increase the synthesis and surface expression of LDL Receptors on their surface . These receptors bind and internalize circulating Low-Density Lipoproteins (LDL-C) from the bloodstream, thereby resulting in a reduction in plasma LDL-C levels throughout the body.

Vascular Pathway Modulation (Pleiotropy)

Independent of the lipid-lowering effect, Ale’s mechanism modulates pathways associated with the vascular endothelium (pleiotropic effects). By influencing inflammatory signaling and endothelial function within the artery walls, the mechanism influences biological processes related to plaque formation and inflammation and modulates activity within these targeted pathways.

Dosage and Administration Information

How Ale (Atorvastatin) is used: Standard Administration Guidelines

Ale, which contains Atorvastatin, is administered exclusively via the oral route as a film-coated tablet. The medicine is used as an adjunct to diet and other non-pharmacological measures as outlined by established guidelines.


Standard Regimen and Frequency

For adult patients, usage typically begins with a starting dose of 10 mg or 20 mg taken once daily. The standard daily dose range is between 10 mg and the recommended maximum daily dose of 80 mg. The maximum dose may be restricted to 20 mg or 40 mg when Ale is co-administered with specific concomitant drugs, such as certain antivirals or macrolide antibiotics.


Timing and Adjustment Rules

Therapy is administered as a once-daily regimen and can be consumed with or without food at any time of the day without impacting the administration pattern. Therapy is designed for chronic, long-term use. Dose adjustments are not made frequently; instead, the dose is assessed and modified at intervals of four weeks or more to maintain the therapeutic regimen. In the event a dose is missed, the protocol is to skip the forgotten dose entirely and resume the routine with the next regularly scheduled dose.


Population-Specific Rules

Specific dose rules exist for certain populations. For instance, no dose adjustment is required for patients with renal impairment. In pediatric patients (10 to 17 years old) being treated for Heterozygous Familial Hypercholesterolemia, the maximum recommended daily dose is restricted to 20 mg.


Connection to the overall use protocol: The guidelines establish a standardized, long-term protocol where the medicine is administered orally as a once-daily regimen. This framework sets clear boundaries for the initial dose, the maximum daily intake, and the minimum duration required between dose adjustments.

Recent Clinical Evidence

Ale: Recent Clinical Evidence

Randomized Controlled Trials (RCTs)

Evidence has been generated from several Randomized Controlled Trials (RCTs) which have explored the effect of Ale on migraine frequency. These studies examined measurements related to changes in migraine symptoms.

One study reported that participants observed a change in attack duration over six months. Other RCTs examined endpoints such as the average number of migraine days per month and participant quality of life. Findings indicated that a portion of participants reported a change in migraine frequency.

Comparative Effectiveness Research

Ale has been studied in comparison to older treatments. Research findings did not include information on clinical recommendations.

A separate investigation examined the combination of Ale with a common preventative therapy. This study explored whether the combination showed differences in changes in attack severity compared to Ale alone. A meta-analysis investigated whether combining the drug with lifestyle changes was associated with different measures of effect.

Special Populations and Safety

Liver and Kidney Function

Studies have evaluated the effects of different doses in adults.

Research has explored the use of the drug in people with liver impairment. Research also evaluated its use in people with kidney issues.

Pediatric Use

Limited evidence has investigated the effect of Ale in a small cohort of adolescents (aged 12-17). These studies evaluated the drug’s effects on pain severity and school attendance. Research continues to evaluate the comparability of outcomes and adverse event incidence with adult populations.

Summary of Findings

Overall, research has explored the effects of Ale. The available studies describe the research on its use in the migraine setting and provide data on frequency and duration of attacks across various study populations.

Frequently Asked Questions (FAQ)

Common questions about Ale (FAQ)


Q: How quickly does Ale usually start to work?

Official information indicates that the medicine's active ingredient reaches its highest concentration in the blood within 1 to 2 hours after a dose. The therapeutic effects, which are measured by changes in your lipid levels, are typically observed in measurements taken after 2 to 4 weeks of consistent treatment.


Q: Can I stop taking Ale suddenly if I feel better?

Regulatory documents state that abrupt discontinuation of Ale is not recommended unless a healthcare professional has advised this course of action. Stopping the medication suddenly may lead to a rapid increase in LDL cholesterol levels, which could impact the ongoing management of cardiovascular health.


Q: Is it normal to feel tired when starting Ale?

Official safety documents include fatigue or malaise (a general feeling of being unwell or tired) as a reported adverse reaction. While this is not expected in the majority of patients, it has been documented in post-marketing reports. If tiredness is severe or persistent, regulatory guidelines suggest consulting with a healthcare provider.


Q: Can Ale affect my ability to drive?

Side effects such as dizziness or blurred vision are noted in the official regulatory profile of Ale. Official information suggests taking caution when driving or operating machinery until the individual understands how the medicine may affect them.


Q: What are the signs that Ale is working for me?

The primary way Ale's therapeutic action is confirmed is through blood tests that measure the reduction in your LDL cholesterol levels. The medicine does not typically produce immediate subjective symptoms that may indicate the therapeutic effect in lowering cholesterol.


Q: What is the 'mechanism of action' of Ale in simple terms?

Ale works primarily in the liver by blocking a key natural enzyme. This enzyme is what the body uses to create its own cholesterol. By reducing internal production, this action signals the liver to draw more of the 'bad' LDL cholesterol out of the bloodstream.


Q: Is Ale safe for older adults?

Official information indicates that the safety profile for adults over 65 years old is similar to that of the general adult population. However, advanced age is officially noted as a factor that may predispose individuals to muscle-related events, meaning monitoring is a factor to consider for this population.


Q: What is the time frame for seeing the full effect of Ale?

To achieve the full therapeutic goal, the official administration guidelines state that the treatment effect is assessed through blood lipid analysis. This measurement is typically performed at least 2 to 4 weeks after starting the treatment or making a dose modification.


Q: What if I have an existing kidney condition and want to take Ale?

According to official prescribing information, renal impairment (kidney issues) generally does not significantly change the concentration of Ale in the body, so a standard dose adjustment is typically not required. Individuals with kidney conditions should be monitored for muscle-related symptoms as a general precaution.


Q: What should I do if a side effect of Ale bothers me a lot?

Regulatory patient counseling advises contacting a healthcare provider immediately if severe or bothersome symptoms are experienced, such as unexplained muscle pain, weakness, or other effects.


Q: Will Ale affect my blood pressure?

Ale is primarily classified as a lipid-lowering agent, and its clinical trials focus on cholesterol reduction and cardiovascular event prevention. Lowering blood pressure is not typically listed as a main clinical indication or a common adverse reaction in official product information.


Q: Is there a link between Ale and weight gain/loss?

Weight gain or loss is not consistently listed as a common or uncommon adverse reaction in the official safety profiles and clinical trial summaries published by regulatory bodies for this medicine.


Q: How is Ale different from supplements I can buy over the counter?

Ale contains the active ingredient Atorvastatin, which is classified as a statin and is legally a prescription-only medicine. This classification means it has undergone rigorous regulatory review, making it fundamentally distinct from over-the-counter dietary supplements.


Q: Will taking Ale change my routine much?

According to the official administration guidelines, the medicine is taken as a single dose once per day. It is officially noted that it can be taken at any time of day and with or without food, allowing for flexibility within a daily routine.


Q: Do studies show Ale is effective for long-term use?

Official regulatory indications are supported by clinical studies that describe the medicine's benefit for the chronic, long-term management of elevated lipid levels and the reduction of cardiovascular event risk.


Q: Can Ale cause sleep problems?

Official safety documents list sleep disturbances, including the specific reaction of insomnia (difficulty falling or staying asleep), as a documented adverse reaction in the regulatory profile of Ale.


Q: Is it possible to be allergic to Ale?

Yes, official regulatory documents state that Ale is contraindicated (prohibited) for use in anyone with a known hypersensitivity (a severe allergic reaction) to its active ingredient, atorvastatin, or to any other component used in the product.


Q: Are there any major drug categories that interact with Ale?

Yes, official warnings highlight interactions with several major categories. These include strong CYP3A4 enzyme inhibitors (like some antifungals or antibiotics) and other lipid-lowering agents (like fibric acid derivatives), which are noted to increase the concentration of Ale and the potential risk of side effects.


Q: Why do some people need a lower dose of Ale?

The initial dose is determined by a healthcare professional based on the individual's characteristics and treatment goals. Dosing may be officially restricted to lower maximum amounts when the medicine is taken alongside specific interacting drugs, which is done to minimize the potential for muscle-related side effects.


Q: Are there different forms of Ale (tablet, liquid, etc.)?

Ale is formally described in regulatory documents as an oral film-coated tablet. Other forms, such as liquids, are not generally noted in the standard prescribing information.


Q: Is Ale approved for use in children?

Official regulatory approval limits the use of Ale in pediatric patients to individuals aged 10 years and older. Even within this age group, use is restricted to treating specific conditions, such as Familial Hypercholesterolemia.


Q: Does Ale affect my mood?

While not common, official post-marketing reports have documented instances of neuropsychiatric side effects, which can include disturbances related to mood and cognitive function. Patients are encouraged to be aware of this possibility based on regulatory reports.

How should Ale be stored and disposed of?

Storage and Disposal Requirements for Ale (Atorvastatin)

The stability of Ale (Atorvastatin) tablets is dependent on adherence to specific storage conditions mandated by official regulatory labeling.


Mandatory Storage and Handling

The product must be stored at Controlled Room Temperature, officially defined as 20^circC to 25^circC (68^circF to 77^circF), with temperature excursions permitted up to 30^circC (86^circF).

The tablets must remain in the original container and be kept tightly closed to ensure protection from moisture and light. The medicine must also be kept out of the sight and reach of children.

Official Disposal Rules

Unused or expired Ale must not be disposed of in household trash or via wastewater (e.g., flushing down the toilet). The disposal process must follow local requirements and is typically handled through an authorized pharmacy or drug take-back program.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ale found in:

A-Z Index: